Pharmaceutical

For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for alopecia areata.

A new campaign from AbbVie highlights the “full selves” of people with conditions treated by the company’s therapies, in a push to show the broader im...

CVS Health, the parent of PBM juggernaut CVS Caremark, won’t presently add Gilead’s twice-yearly pre-exposure prophylaxis drug Yeztugo to its commerci...

Since 2008, the FDA has approved 11 treatments for the rare genetic condition hereditary angioedema, including three in the last two months. The lates...

The countries documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, pharmaceuticals and semiconductors.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its pipeline and meet its near-ter...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen acc...

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition. Ionis set its list price at $57,462 per dose.

A trio of Indian drugmakers—Alembic, Sun and Glenmark—each issued separate voluntary drug recalls due to either the presence of carcinogens or foreign...

On a recent earnings call, the Danish drugmaker's newly appointed CEO signaled that he will look over the company's cost base.